{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T10:09:46Z","timestamp":1778839786877,"version":"3.51.4"},"reference-count":0,"publisher":"ALUNA","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wiadomo\u015bci Lekarskie"],"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This study assessed and compared changes in lipid profile and cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease after six months of liraglutide or dapagliflozin treatment. We also evaluated changes in N-terminal pro-B-type natriuretic peptide levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and methods<\/jats:title>\n                    <jats:p>This prospective, randomized, parallel-group study included 115 adult patients with metabolic dysfunction-associated steatotic liver disease. Participants were randomized into three groups: control (n = 36, lifestyle intervention only), dapagliflozin (n = 41, 10 milligrams daily), or liraglutide (n = 38, titrated to 1.8 milligrams daily). All patients adhered to a Mediterranean diet and moderate physical activity. Lipid profile and N-terminal pro-B-type natriuretic peptide levels were measured at baseline and six months. Cardiovascular risk was assessed using five validated scales: Globorisk, Framingham Risk Score, American College of Cardiology\/American Heart Association atherosclerotic cardiovascular disease Risk Calculator, Prospective Cardiovascular M\u00fcnster Score, and World Health Organization cardiovascular risk charts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All groups showed significant within-group improvements in total cholesterol, low-density lipoprotein cholesterol, triglycerides, and high-density lipoprotein cholesterol (p &lt; 0.001), with liraglutide showing greater lipid improvements intergroup (p &lt; 0.05). Cardiovascular risk scores decreased significantly in all groups, with no differences between them. N-terminal pro-B-type natriuretic peptide levels increased significantly in the control and liraglutide groups, but remained unchanged in the dapagliflozin group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Liraglutide and dapagliflozin are effective in improving lipid profile and reducing cardiovascular risk. Liraglutide showed superior efficacy in lipid improvement. Changes in N-terminal pro-B-type natriuretic peptide require further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.36740\/wlek\/216930","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T09:30:53Z","timestamp":1778837453000},"page":"700-706","source":"Crossref","is-referenced-by-count":0,"title":["Six-month effects of liraglutide and dapagliflozin on lipid profile, cardiovascular risk, and NT-proBNP levels in patients with metabolic dysfunction-associated steatotic liver disease"],"prefix":"10.36740","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5831-8810","authenticated-orcid":false,"given":"Volodymyr","family":"Cherniavskyi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3510-121X","authenticated-orcid":false,"given":"Artem","family":"Akimov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8370-2045","authenticated-orcid":false,"given":"Luiza","family":"Parunian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4157-4428","authenticated-orcid":false,"given":"Viktoriia","family":"Tishchenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4277-079X","authenticated-orcid":false,"given":"Andrii","family":"Seredenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22436","published-online":{"date-parts":[[2026,4,30]]},"container-title":["Wiadomo\u015bci Lekarskie"],"original-title":[],"link":[{"URL":"https:\/\/www.wiadomoscilekarskie.pl\/pdf-216930-139955","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.wiadomoscilekarskie.pl\/pdf-216930-139955","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T09:30:54Z","timestamp":1778837454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wiadomoscilekarskie.pl\/Six-month-effects-of-liraglutide-and-dapagliflozin-on-lipid-profile-cardiovascular,216930,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":0,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"alternative-id":["216930"],"URL":"https:\/\/doi.org\/10.36740\/wlek\/216930","relation":{},"ISSN":["0043-5147","2719-342X"],"issn-type":[{"value":"0043-5147","type":"print"},{"value":"2719-342X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]}}}